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Background: The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial showed in patients with severe
lower limb ischemia (rest pain, tissue loss) who survive for 2 years after intervention that initial randomization to bypass
surgery, compared with balloon angioplasty, was associated with an improvement in subsequent amputation-free survival
and overall survival of about 6 and 7 months, respectively. The aim of this report is to describe the angiographic severity
and extent of infrainguinal arterial disease in the BASIL trial cohort so that the trial outcomes can be appropriately
generalized to other patient cohorts with similar anatomic (angiographic) patterns of disease.
Methods: Preintervention angiograms were scored using the Bollinger method and the TransAtlantic Inter-Society
Consensus (TASC) II classification system by three consultant interventional radiologists and two consultant vascular
surgeons unaware of the treatment received or patient outcomes.
Results: As was to be expected from the randomization process, patients in the two trial arms were well matched in terms
of angiographic severity and extent of disease as documented by Bollinger and TASC II. In patients with the least overall
disease, it tended to be concentrated in the superficial femoral and popliteal arteries, whichwere the commonest sites of disease
overall. The below knee arteries became increasingly involved as the overall severity of disease increased, but the disease in
the above knee arteries did not tend to worsen. The posterior tibial artery was the most diseased crural artery, whereas the
peroneal appeared relatively spared. There was less interobserver disagreement with the Bollinger method than with the
TASC II classification system, which also appears inherently less sensitive to clinically important differences in
infrapopliteal disease among patients with severe leg ischemia.
Conclusions: Anatomic (angiographic) disease description in patients with severe leg ischemia requires a reproducible
scoring system that is sensitive to differences in crural artery disease. The Bollinger system appears well suited for this
purpose, but the TASC II classification system less so. We hope this detailed analysis will facilitate appropriate
generalization of the BASIL trial data to other groups of patients affected by similar anatomic (angiographic) patterns of
disease. ( J Vasc Surg 2010;51:32S-42S.)Severe leg ischemia (SLI), characterized by rest/night
pain and tissue loss (ulceration, gangrene), leads to signif-
icant morbidity and mortality and to the consumption of
considerable health and social care resources in developed
and developing countries.1 The Bypass versus Angioplasty
in Severe Ischaemia of the Leg (BASIL) trial remains the
only multicenter, randomized controlled trial to have com-
pared a revascularization strategy of bypass surgery (BSX)-
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32Sfirst with balloon angioplasty (BAP)-first for the treatment
SLI due to infrainguinal disease. An intention-to-treat anal-
ysis of the BASIL trial has shown that BSX and BAP lead to
similar amputation-free survival (AFS) and overall survival
(OS) out to 2 years from randomization.2 However, for
those patients who survived for2 years after intervention,
initial randomization to surgery was associated with a sig-
nificant increase of 7.3 months in restricted mean OS and a
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AFS during the subsequent mean follow-up of 3.1 years
(range, 1-5.7 years).3 Hospital costs and health-related
quality of life were not significantly different between the
two groups during the first 3 years.4
These data suggest that SLI patients expected to live 2
years should usually be offered BSX, whereas those not ex-
pected to survive2 years should usually be offered BAP.5 A
“by treatment received” analysis of AFS and OS showed that
vein BSX performed significantly better than prosthetic BSX
and that BAP performed better than prosthetic BSX. Thus,
the BASIL trial outcomes and recommendations need to be
considered in the context of the quality of the autogenous
conduit available for BSX in each patient.6
When designing the BASIL trial, the investigators and
participants believed it was important to be able to describe
in detail the anatomic (angiographic) severity and extent of
disease in randomized patients in order to:
1. establish that the patients in the two arms of the trial were
anatomically (angiographically) comparable,
2. facilitate appropriate generalization of the trial data to other
groups of SLI patients affected by similar anatomic (angio-
graphic) patterns of disease,
3. examine the relationship between anatomic (angiographic) pat-
terns of disease and outcomes (AFS, OS) for the BASIL cohort
as a whole,5 and
4. examine the relationship between anatomic (angiographic) pat-
terns of disease and outcomes following BSX and BAP.
To these ends, the 27 participating centers were asked to
forward copies of preintervention angiograms for indepen-
dent, blinded, batch analysis at the trial center. In this report
we address aims 1 and 2 set out above and present an analysis
of those angiograms using the Bollinger scoring method and
the TransAtlantic Inter-Society Consensus (TASC) II classifi-
cation system.7 The relationship between anatomic (angio-
graphic) patterns of disease and outcomes for the BASIL
cohort as a whole (aim 3) has been reported elsewhere,5 and
aim 4 is the subject of on-going further analyses.
METHODS
All patients who participated provided written in-
formed consent, and the study was approved by the Multi-
centre Research Ethics Committee (MREC) for Scotland.
The BASIL trial was registered with the National Research
Register (NRR) and the International Standard Random-
ised Controlled Trials Number (ISRCTN) Scheme (Num-
ber 45398889).
Trial design. The BASIL trial methods have been
reported in detail previously.2-4 Briefly, between August
1999 and June 2004, consultant vascular surgeons and
interventional radiologists in 27 United Kingdom (UK)
hospitals randomized 452 patients with SLI (rest pain or
tissue loss, or both) due to infrainguinal disease, and who
had a pattern of disease on diagnostic imaging that in their
opinion could equally well be treated by BSX or BAP, to a
BSX-first or a BAP-first revascularization strategy.Preintervention angiograms were scored using the
Bollinger method and the TASC II classification system by
three consultant interventional radiologists and two con-
sultant vascular surgeons unaware of the treatment received
or patient outcomes.5 For the Bollinger method, 13 in-
frainguinal arterial segments were assessed:7
● Profunda femoris artery
● Proximal and distal superficial femoral (Pr-SFA, Di-SFA)
● Proximal (above knee) and distal (below knee) popliteal artery
(Pr-PA, Di-PA)
● Tibioperoneal trunk (TPT)
● Proximal (upper half calf) and distal (lower half calf) posterior
tibial (Pr-PTA, Di-PTA)
● Proximal and distal anterior tibial artery (Pr-ATA, Di-ATA)
● Proximal and distal peroneal artery (Pr-PerA, Di-PerA)
● Plantar arch
Each of these segments was scored according to the severity
and extent of disease (Table I). Four severities of lesion are
characterized in the Bollinger method:
● Occlusion of the lumen
● Stenosis 50% of the luminal diameter
● Stenosis 50% but 25%, and
● Plaques impinging 25% of the diameter
Each type of lesion is further categorized as follows by its
extent:
● Single lesion
● Multiple lesions affecting less than half of the segment
● Multiple lesions affecting more than half of the segment
To calculate the additive scores, the individual scores for
each of the three lesion severities are summed in accordance
with the following rules:
1. In the presence of occlusions, stenoses and plaques are not
considered.
2. When both severities of stenoses are present (50% and
50%), plaques (25%) are not considered.
3. For each severity of disease, only one extent of disease category
Table I. Bollinger scoring matrixa
Severity
Extent of diseaseOcclusion
Stenosis
50%
Stenosis
25-49%
Plaques
25%
4 2 1 Single lesion
13 5 3 2 Multiple lesions affecting
less than half the
segment
15 6 4 3 Multiple lesions affecting
more than half the
segment
aThe vertical columns represent the different severities of atherosclerotic
lesions observed. The rows represent the extent of the disease observed in
each segment. The additive score for each segment is obtained by adding the
scores for the four different categories of severity (please see text for details).is scored.
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grams) was scored 0, 4, 6, or 15 according to the degree of
stenosis or occlusion present. Not all sites could be scored on
all angiograms, because although most angiographic studies
included the ankle, forefoot views were often not available.
At the end of randomization, 418 preintervention an-
giograms were available and considered to be of sufficient
quality and completeness to be scorable. These angiograms
were sent in batches to two consultant interventional radi-
ologists (observers 1 and 2) who independently scored the
angiograms according to the Bollinger method. Observers
1 and 2 did not confer and were unaware of the treat-
ment(s) received by the patients or their outcomes. Overall
agreement between observers was good (see Results for
details), but there appeared to be material discrepancies in
73 angiograms in respect to one or more arterial segments.
These angiogram segments were scored by a panel of two
consultant vascular surgeons (observers A and B) and a
third consultant interventional radiologist (observer 3).
This panel did work together and confer, but they were
blind to the scores from observers 1 and 2 and the patients’
treatments and outcomes.
In this way, a consensus Bollinger score was obtained
for each segment from all available data. This process
substantially reduced the proportion of missing data at all
sites except the plantar arch where, as noted above, views of
the forefoot were available for 176 of 224 patients (78.6%)
randomized to a BAP-first strategy and for 164 of 228
patients (71.9%) randomized to a BSX-first strategy. For
the remaining 12 segments only, 1.2% of segments were
missing. Preintervention angiograms were also classified
according to the TASC II criteria for infrainguinal disease
(Fig 1) by observers A and B, who did not confer and were
unaware of the Bollinger scores, treatment(s) received, or
patients’ outcomes.1
Statistical methods. Summary measures for the Bollinger
scores were derived after exploratory data analysis of the rela-
tionships between the scores at different segments. This was
completed without reference to the randomized treatment.
Interobserver agreement for the Bollinger and TASC II
scores was assessed by calculating the percentage agree-
ment from comparable categories. Differences in scores
between categories were assessed by analyses of variance,
and associations between categoric variables were assessed
by 2 tests with Yates correction.
RESULTS
Preintervention angiogramswere available and judged to be
of sufficient quality to be scored using the Bollinger method for
418 patients (92.5%), and scores were available for 5229 of a
possible 5434 arterial segments (96.2%) in those patients. Most
of the missing data related to the plantar arch, where missing or
suboptimal forefoot views made scoring problematic. Bollinger
scores by individual segment in the trial cohort as a whole are
reported in Table II and Fig 2.
As might have been expected, the profunda femoris
artery was relatively spared, and most of the disease was
concentrated in the distal SFA and proximal PA on eitherside of the adductor hiatus, where most patients had occlu-
sive disease. With regard to infrapopliteal disease, the most
severely diseased artery was the PTA, where the proximal or
distal half was occluded in approximately one-half of pa-
tients. The ATA appeared less affected, with distal or prox-
imal occlusions, or both, in approximately one-third of
patients. The PerA was relatively spared; in almost one-half
of patients, the PerA was essentially disease-free (at least
lumenographically) in the proximal or distal half (compared
with less than one-quarter of PTAs and less than one-third
of ATAs). Where forefoot views were available, the plantar
arch was considered occluded in almost 20% of cases.
Correlations between Bollinger scores in the 13 different
arterial segments are reported in Table III. The strongest
positive relationships were between disease in the proximal
and distal SFA, distal PA, and the TPT, TPT and proximal
PTA and PerA, and between the proximal and distal halves of
the three crural vessels (PTA, ATA, and PerA). There were
also some negative correlations; for example, increasing sever-
ity of disease in the SFAwas associatedwithdecreasing severity
of disease in the PA/TPT segment, and vice versa.
Clinical sense and these exploratory analyses led to the
decision to summarize the Bollinger scores as follows for
the purposes of further analysis:
● Mean overall (whole leg) Bollinger score, calculated
from the 12 segments omitting the plantar arch
● Mean above knee Bollinger score for the 4 above knee
segments, where the major contribution is from the SFA
● Mean below knee Bollinger score for the 8 below knee
segments, where the major contribution is from the
crural arteries
In each case, the scores for the segments that could not
be assessed were imputed as the mean of the segments that
were scored for that patient. Because only a small propor-
tion of data were missing, the results were not sensitive to
this imputation choice.
To try to quantify the degree of interobserver variability
associated with the angiographic scoring methods used in
the study, we compared the original Bollinger scores pro-
vided by the first two Bollinger observers (observers 1 and
2) and the TASC II classifications provided by observers A
and B. For the 358 cases where both observers had under-
taken Bollinger scoring of all 12 segments (excluding the
plantar arch), we calculated mean overall (whole leg),
above knee, and below knee Bollinger scores for each
observer in the manner described above. There were 396
angiograms considered adequate for TASC II classification
by both observer A and B.
To compare inter-observer reliability for the two meth-
ods, Bollinger scores were placed into one of four groups
(3, 3-5, 6-8,9) chosen to produce similar group sizes to
those derived from the TASC II classification (classes A, B,
C, and D). The percentages assigned to these Bollinger
score groups and TASC II classes by observers 1 and 2 and
by observers A and B, respectively, are reported in Table IV.
There was no systematic bias between observers 1 and 2
with respect to whole leg, above knee, or below knee
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indeed, they were very similar. However, there was a clear
bias between observers A and B with respect to TASC II
classification (test for trend P  .001). Thus, observer B
considered the cohort to have materially worse angio-
graphic disease than observer A, with this difference being
Fig 1. TransAtlantic Inter-Society Consensus II classi
Suppl S:S51.)apparent in all four TASC II classes.Table V summarizes the differences between the ob-
servers for the Bollinger groups and the TASC II classes.
In about 75% of patients, observers 1 and 2 both placed
the patient in the same Bollinger score group, and in
1% of patients was the discrepancy greater than one
Bollinger score group. By contrast, there was agreement
n. (Taken from Journal of Vascular Surgery 2007;45ficatiowith respect to TASC II class in just50% of the patients
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As was to be hoped and expected from the randomiza-
tion process, the anatomic (angiographic) pattern of disease
in the two trial arms was very similar in terms of individual
arterial segments (Table VI) and whole leg, above knee and
below knee aggregate Bollinger scores (Table VII). The two
arms were also very similar in terms of the distribution of
TASC II classes; data from observer A, who scored the disease
less severely than observer B, are reported in Table VII.
The relationship between the total Bollinger score and the
Fig 2. Distribution of Bollinger scores (0 to 15) in each
each segment occluded are shown with the heaviest sha
have intermediate shading, and the proportions unaffe
PFA, Profunda femoris; Pr-SFA, Di-SFA, proximal an
knee) and distal (below knee); TPT, tibioperoneal tr
(lower half calf) posterior tibial; Pr-AT, Di-AT, proxi
distal peroneal.
Table II. Severity and distribution of arterial disease in th
(BASIL) trial cohort as a whole as quantified by the Bollin
Arterial segment
Patients with different Bol
0 1 2 3 4
Profunda 44.4 9.7 15.9 4.6 9.4
Proximal SFA 13.4 4.1 11.3 12.7 5.8
Distal SFA 4.1 2.6 6.2 5 6.5
Proximal popliteal 11.8 6 10.3 10.8 10.6
Distal popliteal 42.5 3.6 13 7.9 7.5
Tibioperoneal 54.7 1.0 5.1 5.3 9.0
Proximal PT 22.5 1.4 3.1 2.7 8.5
Distal PT 24.8 0.2 1.7 3.2 5.2
Proximal AT 26.6 1.4 4.3 3.4 11.6
Distal AT 37.6 0.7 2.2 2.2 4.5
Proximal peroneal 45.4 0.7 4.8 1.9 11.4
Distal peroneal 57.0 0.5 2 2.7 5.9
Plantar arch 12.1 . . . . . . . . . 14.1
AT, Anterior tibial; PT, posterior tibial; SFA, superficial femoral artery.TASC II score is reported in Table VIII. Although the TASCII and Bollinger scores are generally related, as might have
been expected given their different scope andmethodologies,
there are alsomany cases where they disagree. Examination of
the details of the cases where there were the greatest discrep-
ancies helped to explain the reasons for the differences be-
tween the TASC II and Bollinger scores. The TASC II scores
do not take into account the extent of the disease in the more
distal segments, specifically in the tibial arteries. Cases with a
high Bollinger score but a relatively favorable TASC II classifica-
tionofAorBwere thosewhere the largest burdenof diseasewas
in themore distal segments. The opposite case, when a TASC II
ial segment (plantar arch excluded). The proportions of
at the bottom of each bar, partially affected segments
in each bar are shown unshaded at the top of each bar.
al superficial femoral; Pr-PA, Di-PA, proximal (above
Pr-PT, Di-PT, proximal (upper half calf) and distal
nd distal anterior tibial; Pr-Per, Di-Per, proximal and
ass versus Angioplasty in Severe Ischaemia of the Leg
coring method
scores by individual arterial segment, %
No.5 6 7 8 9 13 15
.9 4.6 0.7 0.2 0.2 3.6 2.7 414
9.6 5.5 3.1 0.2 6.7 21.6 417
.6 8.9 4.1 4.6 1 26.1 26.4 417
.8 6.7 2.4 1.9 0.2 12.0 22.5 417
.1 4.8 1.4 0.5 . . . 7.2 8.4 416
.2 7.0 . . . 0.2 . . . 1.9 14.5 413
.4 8.0 0.7 . . . . . . 7.7 43 414
2.9 0.2 0.2 0.2 8.6 50.6 407
.9 5.8 1.9 0.2 . . . 10.6 30.2 414
.7 3.2 0.2 0.2 . . . 7.7 37.6 404
.8 7.2 . . . . . . . . . 9.9 13.8 414
.0 4.9 . . . . . . . . . 6.4 18.5 405
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IIcriteriabutwherevery littlediseasewas found inthemoredistal
segments.Thus, theBollingermethod appears toprovide a fuller
description of the disease characteristics of the patient with SLI
due to multilevel (distal) disease than does the TASC II classifi-
cation, which focuses largely on the femoropopliteal segment.
Table IX reports the mean whole leg, above knee, and
below knee consensus Bollinger scores for five approxi-
mately equally-sized groups created following ranking of
patients by increasing overall (whole leg without plantar
arch) consensus Bollinger score. One can see that the below
knee Bollinger score increases more rapidly than the above
knee Bollinger scores as the overall severity of disease
worsens. Thus, as described above, the disease in patients
with the least overall burden of infrainguinal disease tends
to be concentrated above the knee, but as the overall
disease burden increases, all three—but especially the PTA
and ATA—become increasingly involved in addition to the
Table III. Correlations (100) between patients’ Bolling
Profunda
Prox
SFA
Distal
SFA
Prox
PA
Distal
PA T
Profunda 11 1 6 7
Prox SFA 11 57 22 31
Distal SFA 1 57 12 28
Prox PA 6 22 12 18
Distal PA 7 31 28 18
Tib-Per 13 25 20 2 41
Prox PT 15 9 16 2 25
Distal PT 14 4 14 3 13
Prox AT 13 7 9 1 19
Distal AT 11 3 10 2 5
Prox Per 13 13 16 6 20
Distal Per 7 4 5 4 13
Plantar arch 6 3 11 3 0
Shaded boxes denote significant correlations (P  .05).
AT, Anterior tibial; PA, popliteal artery; Per, peroneal; PT, posterior tibial;
Table IV. A comparison of Bollinger scores from observe
(TASC) II classifications from observers A and B
Bollinger scores, % in each gr
(n 358)
Mean overall
(whole leg) score
Mean above
knee score
Observer Observer
1 2 1 2
3 7.3 4.5 10.3 11.2
3-5 39.4 39.1 37.2 41.6
6-8 43.0 48.0 38.3 35.2
9 10.3 8.4 14.2 12.0
Scorers 1 and 2 were consultant vascular interventional radiologists who in
scoring system, and scorers A and B were consultant vascular surgeons who
classification. None of the four assessors had knowledge of the treatment su
both observers (Bollinger, n  358; TASC, n  396) are included.more proximal disease (Fig 3).BASIL patients with critical limb ischemia (CLI),
comprising 24% of the cohort with scorable angiograms,
were a subgroup of SLI defined by a highest ankle
pressure 50 mm Hg. They did not have significantly
worse (higher) overall, above knee, or below knee
Bollinger scores than those SLI patients with a highest
ankle pressure of 50 mm Hg (Table IX). However,
those BASIL patients who presented with tissue loss
(68% of the cohort with scorable angiograms) had sig-
nificantly worse (higher) overall and below knee, but not
above knee, Bollinger scores than those patients who
presented with only ischemic rest pain.
More generally, a highly significant negative correla-
tion was found between mean above knee and below knee
Bollinger scores (Pearson correlation0.14; P .005).
This finding is explored further in Table X, which summa-
rizes the observed and expected numbers in a cross-tabula-
tion of above knee and below knee Bollinger scores. The
ores at different arterial segments
r
Prox
PT
Distal
PT
Prox
AT
Distal
AT
Prox
Per
Distal
Per
Plantar
arch
15 14 13 11 13 7 6
9 4 7 3 13 4 3
16 14 9 10 16 5 11
2 3 1 2 6 4 3
25 13 19 5 20 13 0
40 25 19 7 49 23 13
78 23 11 24 4 22
78 12 6 14 4 33
23 12 73 9 6 10
11 6 73 0 7 16
24 14 9 0 54 13
4 4 6 7 54 4
22 33 10 16 13 4
superficial femoral artery; Tib-Per, tibioperoneal.
nd 2 and of TransAtlantic Inter-Society Consensus
TASC II classes, % in each group
(n  396)
Mean below
knee score
Observer Observer
1 2 A B
16.5 16.2 A 15.7 2.8
32.4 27.9 B 41.9 30.1
31.8 32.4 C 29.8 46.5
19.3 23.5 D 12.6 20.7
dently assessed the preintervention angiograms according to the Bollinger
ndently assessed the preintervention angiograms according to the TASC II
ently received or patient outcomes. Only patients with complete data fromer sc
ib-Pe
13
25
20
2
41
40
25
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13rs 1 a
oup
depen
indepeexpected numbers are calculated for the case when there is
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expected ratio of 0.796 is furthest from 1.0 for the group
with the lowest above knee and below knee scores, suggest-
ing that this negative correlation may be because patients
with low scores for both upper and lower leg would not
have been included in the study.
DISCUSSION
Reasons for scoring the trial angiograms. When
designing the BASIL trial, the investigators and partici-
pants believed it was important to be able to describe the
anatomic or at least the angiographic (“lumenographic”)8
severity and extent of disease in randomized patients for a
number of reasons. Firstly, we wished to be able to establish
that patients in the two arms were anatomically (angio-
graphically) comparable. Secondly, given the unique nature
of the trial, we believed it was especially important to
Table V. Difference between observers for Bollinger score
Inter-Society Consensus II (TASC) classification (observer
Score
Percentage of patients by diffe
Two or more
groups/classes
difference (lower)
One grou
differe
(lowe
Bollinger scores (n  358)
Total (whole leg) 0.28 7.2
Below knee 0.28 18.1
Above knee 0.00 10.6
TASC II classification (n  396) 1.26 6.8
Scorers 1 and 2 were consultant vascular interventional radiologists who ind
scoring system and scorers A and B were consultant vascular surgeons who i
classification. None of the four assessors had knowledge of the treatment sub
both observers (Bollinger, n  358; TASC, n  396) are included.
Table VI. Comparison of Bollinger scores by
randomized groups by arterial segment
Mean Bollinger score
BAP first
(n  224)
BSX first
(n  228)
No. Mean (SD) No. Mean (SD)
All sites 208 6.19 (2.23) 210 6.23 (2.22)
Profunda 208 2.53 (3.82) 206 2.18 (3.23)
Proximal SFA 208 6.77 (5.44) 209 6.27 (5.49)
Distal SFA 207 9.64 (5.14) 210 9.19 (5.21)
Proximal popliteal 207 6.90 (5.65) 210 6.98 (5.72)
Distal popliteal 207 3.86 (5.00) 209 3.37 (4.82)
Tibioperoneal trunk 207 3.61 (5.44) 206 3.51 (5.23)
Proximal PTA 207 8.65 (6.54) 207 8.55 (6.36)
Distal PTA 207 9.29 (6.67) 200 9.49 (6.56)
Proximal ATA 207 7.14 (6.24) 207 7.40 (6.36)
Distal ATA 206 7.18 (6.81) 198 7.54 (6.92)
Proximal PerA 207 4.49 (5.71) 207 4.80 (5.65)
Distal PerA 206 3.99 (5.99) 199 4.76 (6.18)
Plantar arch 176 6.38 (4.32) 164 7.13 (4.64)
ATA, Anterior tibial artery; BAP, balloon angioplasty; BSX, bypass surgery;
PerA, peroneal artery; PTA, posterior tibial artery; SD, standard deviation;
SFA, superficial femoral artery.facilitate generalization of the trial data to other groups ofpatients affected by similar anatomic (angiographic) pat-
terns of disease; and, as an important corollary, not to those
patients with different types of clinical and anatomic dis-
ease. Thirdly, we wished to explore the extent to which
anatomic (angiographic) patterns of disease might predict
outcomes (AFS, OS) for the BASIL cohort as a whole5;
and, fourthly, whether it might be possible to predict likely
success or failure of BSX and BAP on the basis the angio-
graphic severity of disease.
To these ends, the 27 participating centers were asked to
forward copies of preintervention imaging, which in almost all
patients was intra-arterial digital subtraction angiography, for
independent, blinded, batch analysis at the trial center. In this
report we address aims one and two set out above by presenting
an analysis of those angiograms using the Bollinger scoring
method. The relationship between the pattern and severity of
disease andoverall survival (aim3)has been reported elsewhere.5
Aim four is not the subject of the present article but is the subject
of on-going further analysis using different methodologies and
tools.9-19
The angiographic characteristics of the BASIL trial
patients. When BASIL trial results are considered, it is
very important to remember that BASIL is emphatically not
a trial of all patients with SLI, of which patients with CLI
defined by an ankle pressure 50 mm Hg are a subgroup,
any more than other vascular randomized controlled trials
have, for example, been a study of all aneurysms or all
carotid artery disease or all claudicant patients. Rather,
BASIL was a trial of those SLI patients whose disease was
due to infrainguinal disease, who were considered to re-
quire immediate or early revascularization, and in whom
the responsible surgeons and interventionalists determined
there was a “gray area of equipoise” for the best manner in
which to achieve that revascularization.20,21 Specifically,
patients were only eligible for randomization in BASIL if
there was true uncertainty about whether a BSX-first or
BAP-first revascularization strategy was in the patient’s best
interests. As previously reported, this group comprised
about one-third of the patients presenting to participating
hospitals with SLI due to infrainguinal disease, and about
server 2 compared with observer 1) and TransAtlantic
mpared with observer A)
in Bollinger group/TASC II class assigned by two observers
All
ss Same group/
class both
observers
One group/class
difference
(higher)
Two or more
groups/classes
difference (higher)
75.42 24.30 0.28 100
71.51 27.93 0.56 100
74.86 25.14 0.00 100
46.97 35.86 9.09 100
dently assessed the pre-intervention angiograms according to the Bollinger
ndently assessed the pre-intervention angiograms according to the TASC II
ntly received or the patients’ outcomes. Only cases with complete data froms (ob
B co
rences
p/cla
nce
r)
6
6
1
2
epen
ndepe
seque70% of those eligible patients were randomized.2
observ
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suggested that at the commencement of the trial, many UK
vascular units were largely offering BAP in preference to
BSX to SLI patients at the “good” end of anatomic and
clinical SLI disease spectrum. Those SLI patients with the
most severe, especially distal, disease were largely being
offered femorodistal BSX rather than BAP. So in a trial that
compared a BSX-first with a BAP-first revascularization
strategy in patients thought to be equally suitable for both,
it was highly likely that the type of BSX undertaken was
going to be less “distal” overall than the totality of surgery
undertaken for SLI and CLI. Similarly, the extent and
complexity of the BAP undertaken in BASIL was likely to
be significantly greater than commonly reported in patients
being treated for disabling claudication. The present data
lend general support to these presumptions, although fur-
ther work is underway to determine if and how the nature
of the BSX and BAP undertaken in BASIL changed during
the recruitment period.
Analysis of the Bollinger scores shows that the two trial
Table VII. Mean consensus Bollinger scores (above knee,
Consensus (TASC) II classification (observer A) by random
Scoring method BAP
Bollinger scores available, No.
All 12 segments (whole leg less plantar arch) 6.
Above knee segments (4) 6.
Below knee segment (8) 6.
TASC II classification by observer A
Not available
A
B
C
D
Total
BAP, balloon angioplasty; BSX, bypass surgery; SD, standard deviation.
Data based on consensus Bollinger scores and TASC II classifications from
Table VIII. The relationship between whole leg
Bollinger scoring and TransAtlantic Inter-Society
Consensus (TASC) II classification
TASC
Mean Bollinger whole leg scorea
0-4.5 4.5-6 6-8 8 All
TASC-A 4 5 2 1 12
TASC-B 36 26 46 14 122
TASC-C 44 45 50 45 184
TASC-D 8 16 29 40 93
All 92 92 127 100 418
aData are based on consensus Bollinger scores (excluding the plantar arch)
and TASC II classifications from observer A.arms were very well matched and that in BASIL patientswith the least overall burden of disease, the disease tends to
be concentrated in the SFA and popliteal artery. However,
as the overall severity of disease increases, the below knee
arteries become increasingly diseased: the PT was the worst
affected crural artery, and the peroneal appeared relatively
spared. Interestingly, but perhaps not surprisingly given the
above considerations, there was a significant negative cor-
relation between mean above knee and the mean below
knee Bollinger scores. Thus, most BASIL patients had
severe disease either above or below the knee.
As suggested above, it appears likely that patients with
w knee, and whole leg) and TransAtlantic Inter-Society
treatment
Randomized treatment
Totaln  224) BSX first (n  228)
8 210
Mean (SD)
.13) 6.20 (2.20)
.63) 5.95 (2.61)
.17) 6.32 (3.15)
No. per category (% of total) Total
.03) 21 (9.21) 39
.34) 9 (3.95) 12
4.55) 67 (29.39) 122
1.50) 93 (40.79) 186
4.55) 38 (16.67) 93
4 228 452
er A.
Table IX. Bollinger scores by increasing overall
angiographic severity of disease, ankle pressure, and
clinical presentation
Variable
Score, mean (SD)
No.
Overall
whole leg
Below
knee
Above
knee
Bollinger score 418
Group 1 83 3.03 (0.78) 1.57 (1.36) 5.97 (2.34)
Group 2 83 4.78 (0.37) 4.38 (1.25) 5.59 (2.44)
Group 3 84 6.13 (0.42) 6.13 (1.47) 6.14 (2.54)
Group 4 84 7.44 (0.37) 8.03 (1.30) 6.25 (2.49)
Group 5 84 9.35 (1.09) 10.21 (2.14) 7.62 (3.08)
Ankle pressure
50 mm Hg 101 6.21 (2.30) 6.13 (3.40) 6.37 (2.74)
50 mm Hg 317 5.99 (2.22) 5.91 (3.22) 6.16 (2.47)
P for difference .40 .55 .49
Tissue loss
Yes 286 6.56 (2.32) 6.46 (3.39) 6.75 (2.71)
No (rest pain
only) 132 5.97 (2.24) 5.90 (3.33) 6.12 (2.64)
P for difference .01 .02 .11
Data based on consensus Bollinger scores.belo
ized
first (
20
31 (2
28 (2
32 (3
18 (8
3 (1
55 (2
93 (4
55 (2
22mild to moderate disease above and below the knee were
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cause their disease was not severe enough to cause SLI or
because they were considered best treated by BAP (no
clinical equipoise). Similarly, it appears that patients with
the severest disease above and below the knee were less
likely to be eligible for randomization because they tended
to be considered by the responsible vascular teams as best
treated by BSX (again, no clinical equipoise). It is clearly
very important that these considerations and the patterns of
disease described here are kept in mind when interpreting
the results of the BASIL trial, especially when trying to
extrapolate the recommendations to other groups of SLI
patients. The angiographic data presented here are reflected
in the BSX and BAP procedures undertaken in BASIL,
which are reported in detail elsewhere.6
The reviewers have criticized the lack of foot views of
sufficient quality to allow reliable scoring of the plantar arch.
We agree that best current practice involves the generation of
such images and that the inclusion of plantar arch data in
various runoff scores may add predictive value, although this
Fig 3. Pattern of disease by five groups according to groups by
overall Bollinger mean score from 1 (best) to 5 (worst). Di-AT,
Distal anterior tibial; Di-PA, distal (below knee) popliteal artery;
Di-Per, distal peroneal; Di-PT, distal (lower half calf) posterior
tibial; Di-SFA, distal superficial femoral artery; PFA, profunda
femoris; Pr-AT, proximal anterior tibial.
Table X. Comparison of above knee and below knee
Bollinger scores (number of cases and ratio of observed
number to the expected number in the case where the
two scores are unrelated)
Mean above
knee
Bollinger
score
No. of cases (observed to expected ratio)a
Total
Mean below knee Bollinger score
5 5-8 8
5 37 (0.796) 42 (1.017) 66 (1.153) 145
5-8 56 (1.065) 51 (1.092) 57 (0.880) 164
8 41 (1.173) 26 (0.838) 42 (0.976) 109
Total 134 119 165 418
aExpected numbers are calculated from the marginal totals, assuming the
two scores are independent. Data based on consensus Bollinger scores.was not the subject of the present report. However, in thepopulation of patients considered by participants as eligible for
randomization in BASIL where suitability for angioplasty was
a sine qua non, for the reasons suggested above, plantar arch
data may not have been as informative as in the entire popu-
lation of SLI and CLI patients.
Choice of scoring systems. Various angiographic
and runoff scoring systems have been described, and
each has different characteristics, strengths, weakness,
and purposes.1,5,7,9-12,16 As discussed above, the purpose
of the present study was to describe the angiographic
patterns of disease in the BASIL cohort as a whole and in
the two arms separately. The purpose was not to try to
relate procedural (BSX or BAP) outcomes to the anatomic
severity and extent of disease or, specifically runoff; those
analyses are ongoing and will be the subject of a further
separate report in due course.
The investigators and participants agreed at the outset
of the trial (late 1990s) that the Bollinger scoring system
would be used to describe the extent and severity of disease
in the BASIL patients because it appeared to be reasonably
user-friendly while at the same time offering considerable
detail throughout the infrainguinal arterial tree. The TASC
II classification did not exist at that time, but in response to
subsequent requests from clinicians who use and value the
TASC system, we have reported here the TASC II classifi-
cation of the BASIL cohort. However, we have chosen not
to make more extensive use of the TASC II classification
when reporting the BASIL trial because, as present data
show, it has significant limitations in this patient group.1
The substantial and highly clinically significant systematic
bias we found between the two observers who indepen-
dently scored the angiograms using the TASC II method
requires further investigation and generalization to further
observers, and this work is on-going.
We have chosen not to emphasize or analyze statisti-
cally a direct comparison between the Bollinger scoring
system and the TASC II classification because we think they
are so different in method, scope, and purpose that it would
be potentially misleading to do so. TASC II largely restricts
itself to the aortoiliac and femoropopliteal segments. All of
the BASIL patients had to have adequate inflow to support
an infrainguinal bypass graft or angioplasty before random-
ization, and almost all the BASIL patients had significant
infrapopliteal disease. Discriminating between SLI patients
with different extents and severities of infrapopliteal artery
disease appears likely to be important in predicting the
success of, and thus the suitability for, different treatments.
Indeed, we have already shown and reported elsewhere that
the extent and severity of distal disease, according to
Bollinger, is a very powerful predictor of overall outcome.6
The TASC II classification, by not permitting a full
description of infrapopliteal disease, gives a less complete
assessment of the type of patient entered into the BASIL
trial. Perhaps not surprisingly, therefore, exploratory anal-
yses have shown only a weak relationship between Bollinger
scores and TASC II group in the BASIL cohort. In partic-
ular, patients can have quite severe infrainguinal disease in
terms of overall Bollinger score but still be classified as a
JOURNAL OF VASCULAR SURGERY
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in to account significant crural artery disease.
Furthermore, as described above, unlike Bollinger,
which appears reproducible, the assessment of BASIL-like
patients by means of TASC II appears to be associated with
a high degree of interobserver error, which is the subject of
further on-going studies. We understand that the TASC
document and classification is currently undergoing further
modifications (personal communication by Professor Lars
Norgen) and it may be that any future “TASC III” classi-
fication of disease will deal with some of these issues. If so,
it may be appropriate to compare the utility of Bollinger
and a new TASC III classification in due course.
Compared with the TASC II scores, there was fairly good
agreement between observers for the Bollinger scores, and
differences could be resolved by a consensus from further
independent scorers. The Bollinger scores were significantly
higher in those with tissue loss than in those without, with the
difference being greatest for the below knee score and not
quite reaching a formal level of significance for the above knee
score. However, those BASIL patients with what somemight
term “true” CLI, as defined by an ankle pressure 50 mm
Hg, did not have worse disease as defined by whole leg, above
knee, or below knee Bollinger scores than those who pre-
sentedwith ankle pressure50mmHg.This findingmay cast
further doubt on the usefulness and appropriateness of an
arbitrary ankle pressure cutoff as part of the international
definition of limb-threatening chronic leg ischemia.1-3,5,6
CONCLUSIONS
Anatomic (angiographic) disease description in SLI pa-
tients requires a scoring system that is sensitive to differences
in both femoropopliteal and infra-trifurcation artery disease.
TheBollinger systemappearswell suited for this purpose,with
practice becomes easy to use, and is associated with acceptably
low levels of interobserver error. The below knee Bollinger
score appears to discriminate better between individuals than
does the above knee score. The TASC II classification appears
to have significant limitations in this patient group due to lack
of reproducibility and definition of crural disease. As was to be
expected from the randomization process, the present analysis
confirms that the patients in the two arms of the BASIL trial
were well matched in terms of anatomic (angiographic) pat-
terns of disease as determined by Bollinger scores and TASC
II classification. The BASIL investigators and participants
hope that the detailed angiographic analysis presented here
will facilitate appropriate generalization of the trial data to
other groups of patients affected by similar anatomic (angio-
graphic) patterns of disease while helping to prevent inappro-
priate generalization to patients who are materially clinically
and angiographically different.
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data collection, data analysis, and writing of the article.
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trial design, data analysis and writing of the article.
Data management and statistical analysis: Dr J. Bell
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Data Monitoring Committee: Professor G. D. O.
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Nicholson, Professor R. Prescott (Professor R. J. Prescott
and Dr A. Lee prepared the data for the committee).
Trial Steering Committee: Professor A. W. Bradbury
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Ms J. Brittenden, Dr J. F. Forbes, Professor F. Gerry R.
Fowkes, Dr P. Gaines, Dr I. Gillespie, Dr S. Girling, Dr K.
McBride, Dr J. Moss, Professor G. Raab, Professor C. V.
Ruckley, Professor G. Stansby, Mr G. Welch, Mr A.
Wilmink, Mr D. J. Adam.
Angiogram assessment and scoring: Dr K. McBride,
Dr R. Ashleigh.
Research nurses: G. Bate, J. Blundell, M. Burrows, J.
Coleman, M. Cullen, C. Devine, L.Holmes, G. Horne, B.
Hughes, J. Innes, M. Ireland, C. Judge, P. Morris-Vincent,
H. Purdie,M. Roseborough, J. Simpson, R. Stuart, T.Uppal,
B. Walsh, B. Watson, V. Wealleans, L. Wilson, S. Zito.BASIL trial Participants
The following consultant vascular surgeons and inter-
ventional radiologists working at the following centers
entered patients into the trial: (number in brackets indi-
cates number of patients entered into BASIL) (*denotes
took part in the BASIL audit): P. Bachoo, J. Brittenden, G.
Cooper, S. Cross, J. Engeset, J. Hussey, E. Macauley, P.
Thorpe, *Aberdeen Royal Infirmary (58); G. Stewart, K.
Osbourne, Ayr Hospital (1); J. Moss, P. Nicholl, S. Silver-
man, J.Wingate, CityHospital, Birmingham (9); D. Adam,
B. Balasubramanian, A. Bradbury, P. Crowe, J. Ferrando,
M. Gannon, M. Henderson, K. Makhdoomi, D. Mosquera,
T. Wilmink, *Heart of England NHS. Foundation Trust
(33); T. Buckenham, R. Chalmers, R. Dawson, S. Fraser, I.
Gillespie, S. Ingram, A. Jenkins, J. Murie, Z. Raza, Edin-
burgh Royal Infirmary (27); N. Jones, D. Lambert, T.
Lees, R. Owen, J. Rose, G. Stansby, M. Wyatt, *Freeman
Hospital, Newcastle (21); D. Byrne, R. Edwards, A.
MacKay, J. Moss, R. Quin, P. Rogers, Gartnavel Hospital,
Glasgow (23); D. Gilmour, D. Leiberman, D. McCarter,
A. Reid, Glasgow Royal Infirmary (1); S. Dodds, M.
Cleesby, A. Jewkes, B. Jones, C. Nelson, A. Parnell, Good
Hope Hospital, Sutton Coldfield (11); P. Bell, A. Bolia,
Leicester Royal Infirmary (1); N. Chalmers, I. Mohan, V.
Smyth, M. Walker, Manchester Royal Infirmary (6); M.
Collins, A. Garnham, G. Mackie, New Cross Hospital,
Wolverhampton (9); P. Stonebridge, J. Houston, Nin-
ewells Hospital, Dundee (1); M. Armon, J. Clarke, J.
Cockburn, J. Colin, S. Girling, S. Scott-Barrett, P. Wilson,
Y. Wilson, *Norfolk &Norwich Hospital (60); J. Beard, T.
Cleveland, P. Chan, P. Gaines, R. Lonsdale, J. Michaels, A.
Nassif, R. Niar, J. Rochester, S. Thomas, R. Wood,
*Northern General Hospital, Sheffield (64); A. Ashour, V.
Bhattachary, A. Nudawi, G. Timmons, Queen Elizabeth
Hospital, Gateshead (2); A.Howd,M. Fleet, H. Ireland, K.
McBride, A. Milne, A. Turner, Queen Margaret Hospital,
Dunfermline (21); G. Ferguson,M. Onwudike, R. Razzaq,
J. Tuck, Royal Bolton Infirmary (5); D. Baker, G. Hamil-
ton, F. Hyint, A. Platts, J. Tibballs, A. Watkinson, Royal
Free Hospital, London (3); K. Choji, R. Grimley, A. Jaya-
tunga, R. Patel, J. Renny, S. Shiralkar, A. Wilinski, Russells
Hall Hospital, Dudley (20); M. Alner, M. Duddy, A.
Edwards, M. Simms, S. Smith, R. Vohra, Selly Oak Hospi-
tal, Birmingham (11); G. MacBain, R. Johnstone, G.
Urquhart, G. Welch, Southern General Hospital, Glasgow
(10); D. Durrans, B. Gwynn, C. Willard, Staffordshire
General Hospital, Stafford (2); M. Thompson, R. Morgan,
St Georges Hospital, London (3); J. Patel, J. Scott, I.
Spark, St James Hospital, Leeds (2); K. Allen, A. Khan, J.
Holland, Walsall Manor Hospital, Walsall (4); R. Ashleigh,
S. Butterfield, R. England, C. McCollum, A. Nasim, M.
Welch, *Wythenshawe Hospital, Manchester (44).
The BASIL trial was only made possible by the enthusiasm
and commitment of the trial centers and we thank all the health
care personnel in those centers for their support of the study.
